ASCO 2026
Kevin Kalinsky, MD, MS, FASCO, on Metastatic Triple-Negative Breast Cancer: More Results From ASCENT-04
Kevin Kalinsky, MD, MS, FASCO, of Winship Cancer Institute of Emory University, provides an update focusing on progression-free survival after next line of treatment and subsequent therapies among pat...
Yelena Y. Janjigian, MD, FASCO, on Safety Results From DESTINY-Gastric03
Yelena Y. Janjigian, MD, FASCO, of Memorial Sloan Kettering Cancer Center, discusses safety results for DESTINY-Gastric03 Part 2 (arms D and F) and Part 4. The trial evaluated first-line fam-trastuzum...
Brendan Heiden, MD, on Lung Cancer Screening Eligibility: Smoking Duration vs Pack-Years
Brendan Heiden, MD, of Washington University School of Medicine, discusses data from a unique real-world cohort of nearly 1 million patients in the Veterans Health Administration; researchers evaluate...
Nicholas C. Turner, MD, PhD, on ER-Positive, HER2-Negative Advanced Breast Cancer: persevERA BC Trial
Nicholas C. Turner, MD, PhD, of the Royal Marsden Hospital, Institute of Cancer Research, discusses results from the primary analysis of the persevERA BC trial, which investigated giredestrant plus pa...
Misty Dawn Shields, MD, PhD, on SCLC: Expert Point of View
Misty Dawn Shields, MD, PhD, of Indiana University Melvin and Bren Simon Comprehensive Cancer Center, shares her perspective on two small cell lung cancer (SCLC) abstracts presented at this year’s mee...
Online Patient Resources About AI and Cancer Found Lacking
Online resources for patients and the general public focused on artificial intelligence (AI) and its uses in cancer research and cancer care were found lacking in a cross-sectional analysis presented ...
Vaccine Plus Pembrolizumab Reduces Risk of Recurrence in High-Risk, Resected Melanoma
The combination of the individualized neoantigen therapy intismeran autogene and pembrolizumab led to an improvement in recurrence-free survival and distant metastasis–free survival rates compared wit...
Phase III Trial Shows Noninferiority for Test-Guided Chemotherapy Decisions in ER-Positive/HER2-Negative Early Breast Cancer
Individuals with estrogen receptor–positive, HER2-negative, high-risk early breast cancer and low Prosigna (PAM50) risk of recurrence (ROR) scores of 60 or less were able to safely skip chemotherapy, ...
Cochrane Review Finds Current Breast Cancer Risk Models Have Limited Accuracy in Women With a Family History of Disease
A comprehensive Cochrane review presented at the 2026 ASCO Annual Meeting suggests that commonly used breast cancer risk prediction models provide only modest accuracy in identifying which women with ...
Addition of Pembrolizumab to Chemotherapy Continues to Demonstrate Overall Survival Benefit in Advanced or Recurrent Endometrial Cancer
Longer follow-up from the phase III NRG-GY018 trial continues to support the addition of pembrolizumab to standard carboplatin/paclitaxel chemotherapy for patients with primary advanced-stage or recur...
Annual Galleri Screening Reduced Stage IV Cancer Diagnoses but Missed Primary Endpoint in First Randomized MCED Trial
Results from the first randomized controlled trial evaluating a multicancer early detection (MCED) blood test suggest that annual screening with the Galleri test may alter the stage at which cancers a...
Sacituzumab Govitecan With Pembrolizumab Extends PFS2 in PD-L1–Positive Metastatic Triple-Negative Breast Cancer
Results from the global phase III ASCENT-04 clinical trial found that sacituzumab govitecan combined with pembrolizumab improved progression-free survival 2 (PFS2) in patients with PD-L1–positive meta...
Oral Metronomic Chemotherapy Plus Ultra-Low-Dose Immunotherapy Improves Survival in Advanced Head and Neck Cancer
According to findings from a phase III trial presented at the 2026 ASCO Annual Meeting (Abstract LBA6007), a low-cost regimen combining triple oral metronomic chemotherapy with ultra-low-dose immunoth...
HCC: TACE Plus STRIDE With or Without Lenvatinib
Results from the phase III EMERALD-3 study found that combining the standard treatment of transarterial chemoembolization (TACE) with the immunotherapy-based STRIDE (single tremelimumab, regular inter...
Symptom-Monitoring App Helps Patients With Advanced Cancer Maintain Quality of Life
Use of a mobile app for proactive symptom monitoring helped patients with advanced cancer who were no longer receiving active anticancer treatment maintain their quality of life and reduced hospital u...
Combining Targeted Immunotherapies With Standard R-CHOP Delays Progression of Aggressive B-Cell Lymphomas
Results from the phase III frontMIND trial show that adding tafasitamab and lenalidomide to R-CHOP (rituximab plus cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone) for first-line tr...
Ghassan K. Abou-Alfa, MD, PhD, FASCO, on Unresectable Embolization-Eligible HCC: Efficacy and Safety Data From EMERALD-3
Ghassan K. Abou-Alfa, MD, PhD, FASCO, of Memorial Sloan Kettering Cancer Center and Weill Medical College at Cornell University, presents efficacy and safety data from the randomized phase III EMERALD...
Angimar Uriepero-Palma, MD, on CLL: Impact of SGLT2 Inhibitors on Patients With Diabetes
Angimar Uriepero-Palma, MD, of Jefferson Einstein Philadelphia Hospital, discusses a study that showed use of sodium-glucose cotransporter 2 (SGLT2) inhibitors was associated with longer 3-year overal...
Bjorn Henning Gronberg, MD, PhD, on Extensive-Stage SCLC: Concurrent TRT and Chemoimmunotherapy
Bjorn Henning Gronberg, MD, PhD, of St. Olav’s Hospital, discusses findings from a phase III trial of concurrent thoracic radiotherapy (TRT) plus platinum/etoposide chemotherapy and the PD-L1 inhibito...
Colton Jones, MD, on GLP-1 RAs for the Prevention of HCC in High-Risk Individuals
Colton Jones, MD, of The University of Texas at San Antonio, talks about the results of a global, multicenter analysis that sought to determine the safety and efficacy of glucagon-like peptide-1 recep...
Shilpa Gupta, MD, on Locally Advanced/Metastatic Urothelial Cancer: Phase III MAIN-CAV Trial
Shilpa Gupta, MD, of Taussig Cancer Institute, discusses findings from the phase III MAIN-CAV study (Alliance A032001) of maintenance cabozantinib and avelumab vs avelumab after first-line platinum-ba...
Jason R. Westin, MD, FASCO, on Updated Safety and Efficacy From the SUNMO Trial in LBCL
Jason R. Westin, MD, FASCO, of The University of Texas MD Anderson Cancer Center, provides an update on the safety and efficacy data from the phase III SUNMO trial, which compared mosunetuzumab and po...
Xin Gao, MD, on Advanced or Metastatic Urothelial Carcinoma: LY4101174
Xin Gao, MD, of Massachusetts General Hospital and Harvard Medical School, discusses initial results from the phase I EXCEED trial of LY4101174, a Nectin-4–targeting antibody-drug conjugate, for patie...
Noelle Cloven, MD, on RAINFOL-03: Actively Recruiting Trial in Pretreated Endometrial Cancer
Noelle Cloven, MD, of Texas Oncology, discusses the actively recruiting RAINFOL-03 (ENGOT-EN-31/GOG-3128) study, a global, phase III, open-label, randomized study of rinatabart sesutecan vs investigat...
Krishnan R. Patel, MD, on High-Risk Prostate Cancer: Clinico-Transcriptomic Risk Stratification
Krishnan R. Patel, MD, of the National Cancer Institute, discusses a combined analysis of the NRG/RTOG 9202, 9413, 9902, and 0521 trials that looked at using clinico-transcriptomic risk stratification...
Mark A. Dickson, MD, on Advanced Dedifferentiated Liposarcoma: SARC041 Trial
Mark A. Dickson, MD, of Memorial Sloan Kettering Cancer Center, presents findings from SARC041, a phase III randomized double-blind study of abemaciclib vs placebo in patients with dedifferentiated li...
Julie R. Brahmer, MD, FASCO, on Previously Untreated Advanced Squamous NSCLC: HARMONi-6 Trial
Julie R. Brahmer, MD, FASCO, of the Bloomberg–Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine, provides expert comme...
Jana de Boniface, MD, PhD, on Breast Cancer With Sentinel Lymph Node Macrometastases: Can Axillary Dissection Be Omitted?
Jana de Boniface, MD, PhD, of Capio Saint Göran's Hospital and Karolinska Institutet, reviews overall survival and patient-reported arm morbidity findings from the SENOMAC trial, which sought to deter...
Christopher A. Barker, MD, on Locally Advanced Unresectable CSCC: RAMPART Trial
Christopher A. Barker, MD, of Memorial Sloan Kettering Cancer Center, reviews the results of the RAMPART study, a phase II, multicenter, single-arm clinical trial evaluating response-adapted definitiv...
Danny Rischin, MD, on Adjuvant Cemiplimab for High-Risk CSCC
Danny Rischin, MD, of Peter MacCallum Cancer Centre, talks about data from the disease-free survival analyses of the C-POST study, which were conducted per high-risk criteria and start time after radi...
Shailender Bhatia, MD, on Adjuvant Avelumab in Patients With Metastatic Merkel Cell Carcinoma
Shailender Bhatia, MD, of the University of Washington and Fred Hutchinson Cancer Center, presents data from the phase III ADAM trial, a multicenter, randomized, double-blinded, placebo-controlled stu...
Jennifer J. Knox, MD, FRCPC, on RASolute 302 Findings: Expert Point of View
Jennifer J. Knox, MD, FRCPC, of Princess Margaret Cancer Centre, provides expert commentary on a phase III study of daraxonrasib vs chemotherapy in previously treated metastatic pancreatic cancer (Abs...
Ronald C. Chen, MD, MPH, FASCO, on High-Risk Muscle-Invasive Urothelial Carcinoma: HRQoL With Pembrolizumab vs Observation
Ronald C. Chen, MD, MPH, FASCO, of the University of Kansas Medical Center, presents health-related quality of life (HRQoL) data from the AMBASSADOR trial, which showed that in patients with high-risk...
Implanted Cesium-131 Tiles Improve Local Control and Survival in Patients With Resected Brain Metastases
A phase III randomized trial presented at the 2026 ASCO Annual Meeting found that implanted tile-based radiation therapy significantly reduced local recurrence and improved overall survival compared w...
Richard Cathomas, MD, on MIBC: Perioperative Intravesical Recombinant BCG Combined With Chemoimmunotherapy
Richard Cathomas, MD, of Cantonal Hospital Graubünden, reviews results from the primary analysis of SAKK 06/19, an open-label single arm phase II trial, which found that the combination of intravesica...
Many Patients With Limited Sentinel Node–Positive Breast Cancer Can Safely Avoid Axillary Dissection, Study Shows
Updated results from the phase III SENOMAC trial suggest that many patients with early-stage breast cancer and limited spread to sentinel lymph nodes can safely forgo axillary lymph node dissection (A...
Adjuvant Selpercatinib Deemed ‘Immediately Practice-Changing’ in Early-Stage RET Fusion–Positive NSCLC
The phase III LIBRETTO-432 trial of adjuvant therapy with the central nervous system (CNS)–penetrant oral RET inhibitor selpercatinib met its primary endpoint of improved event-free survival in patien...
Overall Survival Benefit With Ivonescimab Plus Chemotherapy in Advanced Squamous NSCLC
New findings from the phase III HARMONi-6 trial presented at the 2026 ASCO Annual Meeting showed that the investigational bispecific antibody ivonescimab combined with chemotherapy significantly impro...
Daraxonrasib Extends Median Survival in Previously Treated Pancreatic Cancer
Median Overall survival was nearly doubled among patients with previously treated metastatic pancreatic cancer who received the multiselective RAS(ON) inhibitor daraxonrasib in the phase III RASolute ...
PROTEUS Trial Suggests Perioperative Apalutamide May Improve Outcomes in High-Risk Localized Prostate Cancer
Adding the androgen receptor pathway inhibitor apalutamide to androgen-deprivation therapy (ADT) before and after radical prostatectomy significantly improves outcomes for patients with localized high...
Thomas A. Jandl, MD, PhD, on DLBCL: First-Line Odronextamab Plus Chemotherapy
Thomas A. Jandl, MD, PhD, of Stony Brook University Hospital, discusses data from part 1B of the OLYMPIA-3 trial, which showed that among patients with diffuse large B-cell lymphoma (DLBCL), the safet...
Samuel J. Klempner, MD, FASCO, on Advanced HER2-Negative Gastroesophageal Cancer: Ivonescimab Plus FOLFOX
Samuel J. Klempner, MD, FASCO, of Mass General Brigham Cancer Institute, discusses a single-arm phase II study—which is currently open and enrolling (ClinicalTrials.gov identifier NCT07070466)—evaluat...
Peter Schmid, MD, PhD, FRCP, on ER-Positive HER2-Negative Early Breast Cancer: Giredestrant by Menopausal Status
Peter Schmid, MD, PhD, FRCP, of Queen Mary University of London, shares more data from the phase III lidERA BC clinical trial. This analysis focused on the efficacy and safety of giredestrant in patie...
Siddhartha Yadav, MBBS, MD, on Germline Pathogenic Variants Among Patients With Breast or Ovarian Cancer
Siddhartha Yadav, MBBS, MD, of Mayo Clinic Rochester, talks about a real-world evaluation of germline pathogenic variants in cancer predisposition genes in unselected South Asian women with breast or ...
John M. Burke, MD, on Newly Diagnosed DLBCL: frontMIND Trial
John M. Burke, MD, of SCRI at Rocky Mountain Cancer Centers I The US Oncology Network, presents findings from the phase III frontMIND trial, which evaluated tafasitamab plus lenalidomide and R-CHOP in...
Adam Kibel, MD, on PROTEUS Trial in High-Risk Prostate Cancer: A Surgical Oncologist’s Perspective
Adam Kibel, MD, of Brigham and Women's Hospital, discusses findings from the phase III PROTEUS trial, which evaluated perioperative (neoadjuvant and adjuvant) apalutamide and androgen deprivation ther...
Alicia K. Morgans, MD, FASCO, on Cognitive Effects of Darolutamide vs Enzalutamide
Alicia K. Morgans, MD, FASCO, of Dana-Farber Cancer Institute, discusses data from the phase II ARACOG (AFT-47) randomized clinical trial, which compared the two androgen receptor pathway inhibitors’ ...
Martine J. Piccart-Gebhart, MD, PhD, on Personalizing Treatments in HR-Positive/HER2-Negative Breast Cancer
Martine J. Piccart-Gebhart, MD, PhD, of Jules Bordet Institute, Université Libre de Bruxelles, reviews multiple abstracts discussing avenues of personalized treatment for patients with hormone recepto...
Julie R. Gralow, MD, FACP, FASCO, on Highlights of the 2026 ASCO Annual Meeting
Julie R. Gralow, MD, FACP, FASCO, Chief Medical Officer and Executive Vice President of ASCO, provides an overview of the highlights of this year’s meeting, including practice-changing data included i...
Brian M. Wolpin, MD, MPH, and Eileen M. O’Reilly, MD, on Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
Brian M. Wolpin, MD, MPH, of Dana-Farber Cancer Institute, and Eileen M. O’Reilly, MD, of Memorial Sloan Kettering Cancer Center, describe results from the phase III RASolute 302 trial, which evaluate...
